Biologics CDMO Market

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Biologics Contract Development and Manufacturing Organization(CDMO) estimated at US$ 12710 million in the year 2022, is projected to reach a revised size of US$ 23690 million by 2028, growing at a CAGR of 10.9% during the forecast period 2022-2028.

North American market for Biologics CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global manufacturers of Biologics CDMO include Lonza Group AG, Samsung Biologics, AbbVie, WuXi Biologics, Toyobo, AGC, Thermo Fisher Scientific, ICON Plc and Boehringer Ingelheim, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

The global market for Biologics CDMO in Cell Therapy is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Biological Agent, which accounted for % of the global market of Biologics CDMO in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.

This report aims to provide a comprehensive presentation of the global market for Biologics CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics CDMO.

The Biologics CDMO market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Biologics CDMO market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics CDMO manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

By Company

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

• Lonza Group AG
• Samsung Biologics
• AbbVie
• WuXi Biologics
• Toyobo
• AGC
• Thermo Fisher Scientific
• ICON Plc
• Boehringer Ingelheim
• Fujifilm Diosynth Biotechnologies

By Type

• Biological Agent
• Biosimilar Drug

By Application

• Cell Therapy
• Drug Development
• Others

By Region

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK.
• Italy
• Russia
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Australia
• China Taiwan
• Indonesia
• Thailand
• Malaysia
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE

Scope of Biologics CDMO Market Report